Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placental malaria vaccine
- Development stage
- Preclinical
- Lead developer
- AdaptVac
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The placental malaria vaccine being developed by AdaptVac and the ADVANCE-VAC4PM consortium is a multivalent, virus-like particle (VLP)-based vaccine designed to protect pregnant women and their fetuses from *Plasmodium falciparum* infection. Utilizing AdaptVac's capsid VLP (cVLP) technology, the vaccine incorporates multiple antigens to target different stages of the malaria parasite's life cycle: VAR2CSA to prevent sequestration in the placenta, CSP (circumsporozoite protein) to block liver-stage infection, Pf48/45 to inhibit transmission to mosquitoes, and CIDRα1 to prevent severe disease. This comprehensive approach aims to provide robust immunity against placental malaria, which is a major cause of maternal anemia, stillbirth, and low birth weight. The program is currently in preclinical development with support from EU funding.
- Other names
- ADVANCE-VAC4PM vaccineADVANCE-VAC-4PM vaccineADVANCE-VAC 4PM vaccineVLP-based placental malaria vaccine
02
Targets
VAR2CSA
Beyond the preview
Go deeper on placental malaria vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placental malaria vaccine.